0.292
9.57%
-0.0287
Oragenics Inc stock is traded at $0.292, with a volume of 789.73K.
It is down -9.57% in the last 24 hours and down -11.04% over the past month.
Oragenics, Inc. focuses on developing antibiotics against infectious diseases and treatments for oral mucositis. It is developing OG716, an antibiotic product candidate, which is in nonclinical testing for healthcare-associated infections, as well as other homolog antibiotic product candidates. The company is also developing AG013, which is in Phase II clinical trial for the treatment of oral mucositis in cancer patients. Its product candidates also comprise LPT3-04, a naturally occurring dietary substance for weight loss; and SMaRT Replacement Therapy, a topical treatment applied to the teeth to protect against tooth decay. Oragenics, Inc. has collaboration agreements with Intrexon Corporation and its subsidiary, Intrexon Actobiotics NV to develop AG013 as a potential treatment of oral mucositis for cancer patients. It also has license agreements with LPThera LLC to develop LPT3-04, a weight-loss product candidate; and Texas A&M University System for access to new homologs of the lantibiotic Mutacin 1140 (MU1140) and other lantibiotics, as well as holds licenses from the University of Florida Research Foundation, Inc. for MU1140 product candidates. The company was formerly known as Oragen, Inc. Oragenics, Inc. was founded in 1996 and is headquartered in Tampa, Florida.
See More
Previous Close:
$0.3207
Open:
$0.294
24h Volume:
789.73K
Relative Volume:
1.36
Market Cap:
$3.20M
Revenue:
-
Net Income/Loss:
$-20.26M
P/E Ratio:
-0.0501
EPS:
-5.83
Net Cash Flow:
$-8.25M
1W Performance:
-22.04%
1M Performance:
-11.04%
6M Performance:
-87.55%
1Y Performance:
-91.96%
Oragenics Inc Stock (OGEN) Company Profile
Name
Oragenics Inc
Sector
Industry
Phone
813-286-7900
Address
4902 Eisenhower Boulevard, Suite 125, Tampa, FL
Compare OGEN with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
OGEN | 0.294 | 3.20M | 0 | -20.26M | -8.25M | -5.83 |
VRTX | 467.39 | 119.83B | 10.63B | -479.80M | -1.35B | 13.33 |
REGN | 761.21 | 83.28B | 13.85B | 4.65B | 3.32B | 35.06 |
ARGX | 566.22 | 33.74B | 1.86B | -40.29M | -1.28B | -4.16 |
ALNY | 230.85 | 30.38B | 2.09B | -332.26M | 16.06M | -4.14 |
BNTX | 101.60 | 24.08B | 3.30B | -501.07M | 1.03B | 11.54 |
Oragenics Inc Stock (OGEN) Latest News
Oragenics: Q3 Earnings Snapshot - The Pioneer
StockNews.com Initiates Coverage on Oragenics (NYSE:OGEN) - Defense World
SEC Form DEF 14A filed by Oragenics Inc. - Quantisnow
OGEN stock plunges to 52-week low, touches $0.28 By Investing.com - Investing.com Australia
500: Something went wrong - Investing.com India
OGEN stock plunges to 52-week low, touches $0.28 - Investing.com
Oragenics (NYSE:OGEN) Now Covered by Analysts at StockNews.com - Defense World
Rare Disease Spotlight: Niemann-Pick pipeline behind two approvals - BioCentury
Oragenics, Inc. to Present at the Centurion One Capital 2nd Annual Bahamas Summit - Marketscreener.com
Oragenics, Inc. to Present at The Centurion One Capital 2nd Annual Bahamas Summit - GlobeNewswire
Check Out Oragenics Inc (OGEN)’s Trade Data Rather Than the Analysts’ Views - SETE News
Oragenics Shares Investor Presentation Online - TipRanks
Oragenics inks sales agreement for at-the-market stock offering - Investing.com
Oragenics inks sales agreement for at-the-market stock offering By Investing.com - Investing.com South Africa
Oragenics Inc (OGEN) stock analysis: A comprehensive overview - US Post News
The Future of Oragenics Inc: Analyzing OGEN - The InvestChronicle
Oragenics advances concussion treatment with ONP-002 By Investing.com - Investing.com South Africa
Oragenics advances concussion treatment with ONP-002 - Investing.com India
Metric Deep Dive: Understanding Oragenics Inc (OGEN) Through its Ratios - The Dwinnex
Oragenics, Inc. Updates Shareholders on Concussion Drug Progress and Phase II Trial Preparation - GlobeNewswire
OGEN stock touches 52-week low at $0.37 amid sharp annual decline - Investing.com India
OGEN’s valuation metrics: A comprehensive analysis - US Post News
Oragenics Inc. Successfully Completes Key FDA-Recognized Study for ONP-002 - The Manila Times
EXCLUSIVE: Oragenics Completes Key FDA-Recognized Study For Concussion Drug Candidate - Yahoo Finance
Naples Soap Company Announces Reverse Stock Split - Business Wire
CDE STOCK ALERT: Halper Sadeh LLC Is Investigating Whether the Merger of Coeur Mining, Inc. Is Fair to Shareholders - Business Wire
Ferguson Files Form 8-K and Prospectus Supplement to its Shelf Registration Statement - Business Wire
Photo of Genesco Employees Fitting Students with New Shoes at Ida B. Wells Elementary School in Nashville Available on Business Wire's Website and the Associated Press Photo Network - Business Wire
Webcast Alert: Olympic Steel to Announce Third-Quarter 2024 Financial Results After Market Closes on October 31, 2024 - Business Wire
Reinsurance Group of America Announces Third Quarter Earnings Release Date, Webcast - Business Wire
Graco Inc. Announces Third Quarter 2024 Earnings Conference Call - Business Wire
Momentive Technologies Acquires Spherical Alumina and Spherical Silica Businesses From Sibelco - Business Wire
Wellfit Technologies to Share Expert Insights on AADOM Radio: Demystifying Dental Financing for Profitability - Business Wire
OGEN stock touches 52-week low at $0.38 amid sharp annual decline By Investing.com - Investing.com South Africa
OGEN stock touches 52-week low at $0.38 amid sharp annual decline - Investing.com
Toyoda Gosei Invests in TriOrb Inc., a Startup Developing Mobile Robots With Omnidirectional Movement Capability - Business Wire
LLAP Investors Have Opportunity to Lead Terran Orbital Corporation Securities Fraud Lawsuit with the Schall Law Firm - Business Wire
Oragenics (AMEX:OGEN) Stock Quotes, Forecast and News Summary - Benzinga
Afya Limited to Host Afya Day 2024 on October 29th | Hybrid Event - Business Wire
Expliseat Unveils an Ultra-Light Train Seat at Innotrans - Business Wire
OGEN stock touches 52-week low at $0.47 amid sharp annual decline - Investing.com India
Oragenics grants stock options to top executives - Investing.com India
Oragenics grants stock options to top executives By Investing.com - Investing.com Canada
Oragenics Inc Stock (OGEN) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):